Research published in Science on Wednesday reports that vaccinating pregnant mice with capsular polysaccharide bioconjugates protected their newborn pups against sepsis caused by Klebsiella pneumoniae, according to Science | AAAS.
The study points to maternal immunization as a possible route for defending newborns against the bacterium, which the research links to neonatal sepsis. Rather than immunizing the infant directly, the approach relies on transferring protection from the vaccinated mother to her offspring.
Klebsiella pneumoniae is a bacterial pathogen, and the work centers on capsular polysaccharide bioconjugates as the vaccine platform. In the experiments described by Science | AAAS, the maternal shot was followed by protection in the young mice when they were exposed to the infection.
Because the findings come from a murine model, they establish a proof of concept in animals rather than a confirmed result in humans. The headline and summary released by Science | AAAS do not include data on how long the protection lasted, how it compares with other vaccine strategies, or which components of the immune response were responsible.
Neonatal sepsis remains a serious concern because newborns have limited immune defenses, and vaccinating the mother is one way researchers have tried to close that gap before an infant can be immunized. The new work adds Klebsiella pneumoniae to the list of targets being explored through that strategy.
What to watch next: whether follow-up studies test this bioconjugate approach against additional Klebsiella strains and move it toward human trials.
